Balaji Prasad
Stock Analyst at Barclays
(3.58)
# 862
Out of 5,124 analysts
147
Total ratings
50%
Success rate
5.69%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $6.65 | +275.94% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $12.60 | -12.70% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $25.88 | -7.26% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $12.45 | -27.71% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $170.00 | +17.65% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $22.63 | -16.04% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $81.88 | -26.72% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $125.82 | +93.93% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $7.17 | +234.73% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $37.36 | -41.11% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $676.53 | -23.14% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $31.21 | -16.69% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $188.97 | -15.33% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.04 | +21.08% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $5.13 | +250.88% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.34 | +130.41% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.43 | +390.54% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $6.65
Upside: +275.94%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $12.60
Upside: -12.70%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $25.88
Upside: -7.26%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $12.45
Upside: -27.71%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $170.00
Upside: +17.65%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $22.63
Upside: -16.04%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $81.88
Upside: -26.72%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $125.82
Upside: +93.93%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $7.17
Upside: +234.73%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $37.36
Upside: -41.11%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $676.53
Upside: -23.14%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $31.21
Upside: -16.69%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $188.97
Upside: -15.33%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.04
Upside: +21.08%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $5.13
Upside: +250.88%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.34
Upside: +130.41%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.43
Upside: +390.54%